Showing results (291-300 of 311) with videos related to
Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group studyH S Hochster, K M Kim, M D Green, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.Journal of Travel Medicine|March 7, 2001
Malaria in Brazilian military personnel deployed to AngolaJ L Sanchez, I Bendet, M Grogl, et al.Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.The Medical Journal of Australia|October 2, 1989
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary reportW P Sheridan, A W Boyd, M D Green, et al.Journal of Animal Science|March 30, 2010
Establishing an appropriate mode of comparison for measuring the performance of marbling score output from video image analysis beef carcass grading systemsC B Moore, P D Bass, M D Green, et al.Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.Cancer Chemotherapy and Pharmacology|April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.Pageof 32